Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CLPP | Q16740 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777580 | 0.99 | FAAH (0.51) | FAAHCACNA1BHRH3HIF1AALDH1A1 | |
| SCHEMBL5778653 | 0.88 | TMEM97 (0.50) | FAAHHRH3ALDH1A1HPGDKDM4E | |
| SCHEMBL5776677 | 0.83 | FAAH (0.45) | FAAH | |
| SCHEMBL5775158 | 0.83 | FAAH (0.48) | FAAHALDH1A1HPGDKDM4EMEN1 | |
| SCHEMBL5774446 | 0.82 | FAAH (0.46) | FAAHMEN1NPC1RAB9AKMT2A | |
| SCHEMBL5772604 | 0.81 | FAAH (0.52) | FAAHALDH1A1HPGDKDM4ENPSR1 | |
| SCHEMBL5774958 | 0.81 | FAAH (0.49) | FAAHALDH1A1HPGDKDM4EMEN1 | |
| SCHEMBL1549789 | 0.81 | FAAH (0.56) | FAAHALDH1A1HPGDKDM4EMEN1 | |
| SCHEMBL5777690 | 0.80 | HRH3 (0.47) | CACNA1BHRH3HIF1AALDH1A1HPGD | |
| SCHEMBL11982568 | 0.79 | FAAH (0.54) | FAAHALDH1A1HPGDKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | FAAH 23/4885CACNA1B 1093/4885HRH3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.